High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation

Katre, 1993, The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential, Adv. Drug Deliv. Rev., 10, 91, 10.1016/0169-409X(93)90005-O Veronese, 1996, Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol), J. Control. Release, 40, 199, 10.1016/0168-3659(95)00185-9 Bailon, 2001, Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon-alpha 2a for the treatment of hepatitis, C. Bioconjug. Chem., 12, 195, 10.1021/bc000082g Parkinson, 2003, Pegvisomant in the treatment of acromegaly, Adv. Drug Deliv. Rev., 55, 1303, 10.1016/S0169-409X(03)00111-X Edwards, 2003, Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases, Adv. Drug Deliv. Rev., 55, 1315, 10.1016/S0169-409X(03)00112-1 Whelan, 2005, Beyond PEGylation, Drug Discov. Today, 10, 301, 10.1016/S1359-6446(05)03387-8 Yoshioka, 2004, Optimal site-specific PEGylation of mutant TNF-α improves its antitumor potency, Biochem. Biophys. Res. Commun., 315, 808, 10.1016/j.bbrc.2004.01.125 Cazalis, 2004, C-terminal site-specific PEGylation of a truncated thrombomodulin mutant with retention of full bioactivity, Bioconjug. Chem., 15, 1005, 10.1021/bc049903y Youn, 2005, Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential, Int. J. Biochem. Cell Biol., 37, 1525, 10.1016/j.biocel.2005.01.014 Kinstler, 2002, Mono-N-terminal poly(ethylene glycol)–protein conjugates, Adv. Drug Deliv. Rev., 54, 477, 10.1016/S0169-409X(02)00023-6 Yamamoto, 2003, Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity, Nat. biotechnol., 21, 546, 10.1038/nbt812 Moreadith, 2003, Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction, Adv. Drug Deliv. Rev., 55, 1337, 10.1016/S0169-409X(03)00113-3 Rosendahl, 2005, A long-acting, highly potent interferon α-2 conjugate created using site-specific PEGylation, Bioconjug. Chem., 16, 200, 10.1021/bc049713n Natarajan, 2005, Characterization of site-specific scFv PEGylation for tumor-targeting pharmaceuticals, Bioconjug. Chem., 16, 113, 10.1021/bc0498121 Youn, 2004, Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1–29), J. Chromatogr., A, 1061, 45, 10.1016/j.chroma.2004.10.062 Na, 2004, Stability of PEGylated salmon calcitonin in nasal mucosa, J. Pharm. Sci., 93, 256, 10.1002/jps.10537 Lu, 1994, Pegylated peptides II: solid-phase synthesis of amino-, carboxy- and side-chain pegylated peptides, Int. J. Protein Res., 43, 127, 10.1111/j.1399-3011.1994.tb00513.x F. Liu, S.W. Kim, M. Baudys, Synthesis of insulin derivatives, US Patent 6,323,311, 2001. Deiters, 2004, Site-specific PEGylation of proteins containing unnatural amino acids, Bioorg. Med. Chem. Lett., 14, 5743, 10.1016/j.bmcl.2004.09.059 Lee, 1999, Isolation, characterization, and stability of positional isomers of mono-PEGylated salmon calcitonins, Pharm. Res., 16, 813, 10.1023/A:1018861616465 Youn, 2006, Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy, J. Control. Release, 114, 334, 10.1016/j.jconrel.2006.06.007 Lee, 1999, Preparation and characterization of polyethylene glycol modified salmon calcitonins, Pharm. Dev. Technol., 4, 269, 10.1081/PDT-100101361 Lee, 2003, Intranasal delivery of PEGylated salmon calcitonins: hypocalcemic effects in rats, Calcif. Tissue Int., 73, 545, 10.1007/s00223-002-0034-9 Na, 2001, Identification of the modifying sites of mono-PEGylated salmon calcitonins by capillary electrophoresis and MALDI-TOF mass spectrometry, J. Chromatogr., B., 754, 259, 10.1016/S0378-4347(00)00599-5 Lee, 2005, Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1, Bioconjug. Chem., 16, 377, 10.1021/bc049735+ Katayama, 2001, Discovery of a non-peptide small molecule that selectively mimics the biological actions of calcitonin, Biochim. Biophys. Acta, 1526, 183, 10.1016/S0304-4165(01)00125-8 Mansoor, 2005, Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect, Pharm. Dev. Technol., 10, 389, 10.1081/PDT-200065686 Youn, 2004, Pulmonary delivery of Lys18-mono-PEGylated salmon calcitonin, AAPS J., 6, T2162 Wylie, 2001, Carboxyalkylated histidine is a pH-dependent product of PEGylation with SC-PEG, Pharm. Res., 18, 1354, 10.1023/A:1013006515587 Azria, 1989 Lang, 1996, Proteolysis of human calcitonin in excised bovine nasal mucosa: elucidation of the metabolic pathway by liquid secondary ionization mass spectrometry (LSIMS) and matrix assisted laser desorption ionization mass spectrometry (MALDI), Pharm. Res., 13, 1679, 10.1023/A:1016492723930